Bone Therapeutics

Miguel Forte, M.D., Ph.D., CEO
Gosselies, Belgium
(NASDAQ: BOTHE)
Bone Therapeutics is a listed, clinical-stage, cell therapy company committed to rebuilding lives of patients suffering from debilitating bone and joint conditions. Leveraging its extensive expertise in mesenchymal stromal cells, bone physiology, and patented manufacturing technology, Bone Therapeutics is developing a commercially ready, allogeneic and off-the-shelf bone cell therapy platform, ALLOB, and a protein solution for osteoarthritis pain, JTA-004, which are designed to offer patients and physicians best-in-class treatment options. Currently in Phase II/III clinical development, Bone Therapeutics’ advanced product portfolio targets large orthopaedic conditions with high unmet needs, such as knee osteoarthritis, unhealed fractures, and spinal fusion.
www.bonetherapeutics.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions